RecruitingNCT06241326

Immunotherapy for Hepatocellular Carcinoma

A Real-world Study of Immunotherapy-based Combination Therapies in Chinese Patients With Hepatocellular Carcinoma

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Enrollment

11,000 participants

Start Date

Mar 1, 2024

Study Type

OBSERVATIONAL

Conditions

Hepatocellular Carcinoma Immunotherapy

Summary

This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting data from patients with hepatocellular carcinoma (a type of liver cancer) who are receiving immunotherapy-based treatment combinations. The goal is to build real-world evidence about how these treatments work and to identify which patients benefit most. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with liver cancer (hepatocellular carcinoma) confirmed by imaging or biopsy - Your doctor believes you may benefit from immunotherapy-based combination treatment - You are willing to provide baseline information including medical history and imaging results **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your doctor identifies another reason that makes participation inappropriate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.